









市場行情
/
股票
/
nasdaq-alny
/

Alnylam Pharmaceuticals Inc

ALNY

400.590USD

-0.100-0.02%

收盤 12/26, 16:00（美東）報價延遲15分鐘

52.79B總市值

1233.61本益比TTM



Alnylam Pharmaceuticals Inc

400.590

-0.100-0.02%

概覽公司財務分析

概覽

公司

財務

分析

關於 Alnylam Pharmaceuticals Inc 公司

Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.

Alnylam Pharmaceuticals Inc簡介



公司代碼ALNY

公司名稱Alnylam Pharmaceuticals Inc

上市日期May 28, 2004

CEOGreenstreet (Yvonne L)

員工數量2230

證券類型Ordinary Share

年結日May 28

公司地址675 W Kendall St

城市CAMBRIDGE

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編02142-1168

電話16175518200

網址https://www.alnylam.com/

公司代碼ALNY

上市日期May 28, 2004

CEOGreenstreet (Yvonne L)

Alnylam Pharmaceuticals Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Yvonne L. Greenstreet, M.D.

Chief Executive Officer, Director

69.39K

+5.43%

Mr. Jeffrey V. (Jeff) Poulton

Chief Financial Officer, Executive Vice President

54.11K

+7.83%

Mr. Tolga Tanguler

Chief Commercial Officer

27.44K

+5.56%

Dr. Dennis A. Ausiello, M.D.

Independent Director

4.41K

Dr. Margaret A. Hamburg, M.D.

Independent Director

911.00

+569.85%

Dr. Olivier Brandicourt, M.D.

Independent Director

775.00

Mr. Peter N. Kellogg

Independent Director

775.00

Ms. Colleen F. Reitan

Independent Director

Ms. Amy W. Schulman, J.D.

Independent Chairman of the Board

Dr. Pushkal P. Garg, M.D.

Executive Vice President, Chief Research and Development Officer

名稱

名稱/職務

職務

持股

持股變動

Dr. Yvonne L. Greenstreet, M.D.

Chief Executive Officer, Director

69.39K

+5.43%

Mr. Jeffrey V. (Jeff) Poulton

Chief Financial Officer, Executive Vice President

54.11K

+7.83%

Mr. Tolga Tanguler

Chief Commercial Officer

27.44K

+5.56%

Dr. Dennis A. Ausiello, M.D.

Independent Director

4.41K

Dr. Margaret A. Hamburg, M.D.

Independent Director

911.00

+569.85%

Dr. Olivier Brandicourt, M.D.

Independent Director

775.00

收入明細

單位: USD更新時間: 10月6日週一

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

業務USD

名稱

營收

佔比

AMVUTTRA

491.95M

63.59%

GIVLAARI

80.85M

10.45%

ONPATTRO

52.54M

6.79%

Other

50.67M

6.55%

OXLUMO

46.87M

6.06%

其他

50.81M

6.57%

地區USD

名稱

營收

佔比

United States

454.57M

58.75%

Europe

157.01M

20.29%

Net revenues from collaborations

61.50M

7.95%

Rest of World

60.63M

7.84%

Royalty revenue

39.98M

5.17%

業務

地區

業務USD

名稱

營收

佔比

AMVUTTRA

491.95M

63.59%

GIVLAARI

80.85M

10.45%

ONPATTRO

52.54M

6.79%

Other

50.67M

6.55%

OXLUMO

46.87M

6.06%

其他

50.81M

6.57%

股東統計

更新時間: 11月17日週一

持股股東

股東類型

持股股東

佔比

Capital World Investors

12.44%

Fidelity Management & Research Company LLC

12.04%

The Vanguard Group, Inc.

10.22%

Capital Research Global Investors

5.47%

BlackRock Institutional Trust Company, N.A.

4.98%

其他

54.85%

持股股東

佔比

Capital World Investors

12.44%

Fidelity Management & Research Company LLC

12.04%

The Vanguard Group, Inc.

10.22%

Capital Research Global Investors

5.47%

BlackRock Institutional Trust Company, N.A.

4.98%

其他

54.85%

股東類型

持股股東

佔比

Investment Advisor

66.37%

Investment Advisor/Hedge Fund

23.04%

Hedge Fund

3.83%

Research Firm

2.50%

Sovereign Wealth Fund

1.70%

Pension Fund

1.29%

Bank and Trust

1.20%

Corporation

1.05%

Individual Investor

0.42%

機構持股



更新時間: 12月8日週一

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

1441

132.38M

102.07%

-8.88K

2025Q3

1468

132.43M

102.39%

+2.53M

2025Q2

1335

129.81M

101.55%

+2.82M

2025Q1

1292

127.17M

99.72%

-2.77M

2024Q4

1248

125.34M

101.87%

-989.05K

2024Q3

1210

126.51M

99.20%

+3.13M

2024Q2

1165

122.70M

94.98%

+5.27M

2024Q1

1152

117.38M

97.56%

-6.00M

2023Q4

1149

120.10M

100.10%

-712.55K

2023Q3

1103

121.13M

101.32%

-503.11K

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Capital World Investors

16.81M

12.82%

+55.38K

+0.33%

Jun 30, 2025

Fidelity Management & Research Company LLC

15.05M

11.48%

+427.38K

+2.92%

Jun 30, 2025

The Vanguard Group, Inc.

13.24M

10.1%

+238.24K

+1.83%

Jun 30, 2025

Capital Research Global Investors

7.19M

5.49%

+36.93K

+0.52%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

6.53M

4.98%

-199.00K

-2.96%

Jun 30, 2025

JP Morgan Asset Management

1.79M

1.37%

-87.08K

-4.64%

Jun 30, 2025

State Street Investment Management (US)

3.17M

2.42%

-193.48K

-5.75%

Jun 30, 2025

Baillie Gifford & Co.

3.03M

2.31%

-625.72K

-17.11%

Jun 30, 2025

Geode Capital Management, L.L.C.

2.40M

1.83%

+75.94K

+3.27%

Jun 30, 2025

Dodge & Cox

3.20M

2.44%

-154.67K

-4.61%

Jun 30, 2025

持股ETF



更新時間: 12月2日週二

機構名稱

佔比

Global X Genomics & Biotechnology ETF

6.48%

ProShares Ultra Nasdaq Biotechnology

5.81%

Invesco Nasdaq Biotechnology ETF

5.77%

Franklin Genomic Advancements ETF

5.35%

iShares Biotechnology ETF

5.07%

VanEck Biotech ETF

4.56%

American Century Focused Dynamic Growth ETF

3.76%

Goldman Sachs Future Health Care Equity ETF

3.42%

First Trust NYSE Arca Biotechnology Index Fund

3.33%

Invesco NASDAQ Next Gen 100 ETF

3.28%

Global X Genomics & Biotechnology ETF

佔比6.48%

ProShares Ultra Nasdaq Biotechnology

佔比5.81%

Invesco Nasdaq Biotechnology ETF

佔比5.77%

Franklin Genomic Advancements ETF

佔比5.35%

iShares Biotechnology ETF

佔比5.07%

VanEck Biotech ETF

佔比4.56%

American Century Focused Dynamic Growth ETF

佔比3.76%

Goldman Sachs Future Health Care Equity ETF

佔比3.42%

First Trust NYSE Arca Biotechnology Index Fund

佔比3.33%

Invesco NASDAQ Next Gen 100 ETF

佔比3.28%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Alnylam Pharmaceuticals Inc的前五大股東是誰？



Alnylam Pharmaceuticals Inc的前五大股東如下：
Capital World Investors
持有股份：16.81M
佔總股份比例：12.82%。
Fidelity Management & Research Company LLC
持有股份：15.05M
佔總股份比例：11.48%。
The Vanguard Group, Inc.
持有股份：13.24M
佔總股份比例：10.10%。
Capital Research Global Investors
持有股份：7.19M
佔總股份比例：5.49%。
BlackRock Institutional Trust Company, N.A.
持有股份：6.53M
佔總股份比例：4.98%。